[
  {
    "title": "Is Bristol-Myers Squibb (BMY) The Best Healthcare Dividend Stock to Invest in?",
    "published": 1742821749,
    "posting_price": 60.79000092,
    "close_price": 61.02000046,
    "percent_change": 0.37835094
  },
  {
    "title": "8 key drug patents expiring soon \u2014 and what it means for the market",
    "published": 1742806800,
    "posting_price": 60.79000092,
    "close_price": 61.02000046,
    "percent_change": 0.37835094
  },
  {
    "title": "Is Bristol-Myers Squibb (BMY) Among the Cheap Stocks to Buy According to Billionaires?",
    "published": 1742673883
  },
  {
    "title": "Bristol-Myers Squibb Company (BMY): Among Incredibly Cheap Dividend Stock to Buy Now",
    "published": 1742577940,
    "posting_price": 60.22999954,
    "close_price": 61.06999969,
    "percent_change": 1.39465409
  },
  {
    "title": "Is Bristol-Myers Squibb Company (BMY) The Best Undervalued Stock to Buy According to Billionaires?",
    "published": 1742482746,
    "posting_price": 59.86000061,
    "close_price": 60.41999817,
    "percent_change": 0.93551212
  },
  {
    "title": "Is Bristol-Myers Squibb (BMY) the Most Undervalued Biotech Stock to Invest In?",
    "published": 1742394833,
    "posting_price": 59.86000061,
    "close_price": 60.08000183,
    "percent_change": 0.36752626
  },
  {
    "title": "Bristol-Myers Squibb Company (BMY): A Bull Case Theory",
    "published": 1742232900,
    "posting_price": 59.15999985,
    "close_price": 59.99000168,
    "percent_change": 1.40297808
  },
  {
    "title": "EC approves Bristol Myers Squibb\u2019s follicular lymphoma CAR T therapy",
    "published": 1742203332,
    "posting_price": 59.15999985,
    "close_price": 59.99000168,
    "percent_change": 1.40297808
  },
  {
    "title": "Why Bristol-Myers Squibb Company (BMY) Went Down On Friday?",
    "published": 1742022159
  },
  {
    "title": "Bristol-Myers Squibb (NYSE:BMY) Gets EC Nod For Breyanzi In NHL Treatment",
    "published": 1741973244,
    "posting_price": 59.84000015,
    "close_price": 59.00999832,
    "percent_change": -1.38703514
  },
  {
    "title": "Bristol Myers Squibb Receives Approval from the European Commission to Expand Use of CAR T Cell Therapy Breyanzi for Relapsed or Refractory Follicular Lymphoma",
    "published": 1741949940,
    "posting_price": 59.84000015,
    "close_price": 59.00999832,
    "percent_change": -1.38703514
  },
  {
    "title": "Big Pharma Walked Away From Mental Health. Why Some Are Coming Back.",
    "published": 1741944600,
    "posting_price": 59.84000015,
    "close_price": 59.00999832,
    "percent_change": -1.38703514
  },
  {
    "title": "Gilead (GILD) Up 10.3% Since Last Earnings Report: Can It Continue?",
    "published": 1741879829,
    "posting_price": 59.99000168,
    "close_price": 60.27999878,
    "percent_change": 0.48340905
  },
  {
    "title": "Is Bristol-Myers Squibb Company (BMY) the Best Pharma Stock to Buy According to Hedge Funds?",
    "published": 1741804361,
    "posting_price": 60.72000122,
    "close_price": 59.81000137,
    "percent_change": -1.4986822
  },
  {
    "title": "3 Pharma Stocks That Are Money-Printing Machines in 2024",
    "published": 1713217891,
    "posting_price": 46.59405088,
    "close_price": 46.73857117,
    "percent_change": 0.31016897
  },
  {
    "title": "Bristol Myers Squibb (BMY) Advances While Market Declines: Some Information for Investors",
    "published": 1713217820,
    "posting_price": 46.59405088,
    "close_price": 46.73857117,
    "percent_change": 0.31016897
  },
  {
    "title": "In the wake of Bristol-Myers Squibb Company's (NYSE:BMY) latest US$5.7b market cap drop, institutional owners may be forced to take severe actions",
    "published": 1713189617,
    "posting_price": 46.59405088,
    "close_price": 46.73857117,
    "percent_change": 0.31016897
  },
  {
    "title": "Better Buy: Bristol Myers Squibb or the Vanguard S&P 500 ETF?",
    "published": 1713187800,
    "posting_price": 46.59405088,
    "close_price": 46.73857117,
    "percent_change": 0.31016897
  },
  {
    "title": "Market Whales and Their Recent Bets on BMY Options",
    "published": 1713184680,
    "posting_price": 46.59405088,
    "close_price": 46.73857117,
    "percent_change": 0.31016897
  },
  {
    "title": "How To Invest $100,000 Today With Peace Of Mind",
    "published": 1712998800
  },
  {
    "title": "Pomerantz Law Firm Investigates Claims on Behalf of Investors of Bristol-Myers Squibb Company - BMY",
    "published": 1712933169,
    "posting_price": 47.24922094,
    "close_price": 46.51697159,
    "percent_change": -1.54975963
  },
  {
    "title": "The Zacks Analyst Blog Highlights Bristol Myers, Moderna, 2seventy bio, Amylyx Pharmaceuticals and Syros Pharmaceuticals",
    "published": 1712928120,
    "posting_price": 47.24922094,
    "close_price": 46.51697159,
    "percent_change": -1.54975963
  },
  {
    "title": "Bristol Myers Squibb: Seriously Undervalued At Peak Pessimism (Rating Upgrade)",
    "published": 1712923590,
    "posting_price": 47.24922094,
    "close_price": 46.51697159,
    "percent_change": -1.54975963
  },
  {
    "title": "Wall Street Favorites: 3 Warren Buffett Stocks With Strong Buy Ratings for April 2024",
    "published": 1712919600,
    "posting_price": 47.24922094,
    "close_price": 46.51697159,
    "percent_change": -1.54975963
  },
  {
    "title": "Healthpeak Properties: A Quality Healthcare REIT That Should Get Back To Dividend Growth",
    "published": 1712905200,
    "posting_price": 47.24922094,
    "close_price": 46.51697159,
    "percent_change": -1.54975963
  },
  {
    "title": "U.S. Wide-Moat Stocks On Sale - The April 2024 Heat Map",
    "published": 1712898708,
    "posting_price": 47.24922094,
    "close_price": 46.51697159,
    "percent_change": -1.54975963
  },
  {
    "title": "Analysts Have Conflicting Sentiments on These Healthcare Companies: Bristol-Myers Squibb (BMY) and Roche Holding AG (OtherRHHVF)",
    "published": 1712898060,
    "posting_price": 47.24922094,
    "close_price": 46.51697159,
    "percent_change": -1.54975963
  },
  {
    "title": "Bristol-Myers Squibb: A Buy Rating on Undervaluation and Promising Product Portfolio",
    "published": 1712895960,
    "posting_price": 47.24922094,
    "close_price": 46.51697159,
    "percent_change": -1.54975963
  },
  {
    "title": "Small-Cap Cancer Drug Developer Agenus' Highlights Encouraging Data From Colorectal Cancer, But Funding Concerns Loom",
    "published": 1712884980,
    "posting_price": 47.24922094,
    "close_price": 46.51697159,
    "percent_change": -1.54975963
  },
  {
    "title": "If You Can Only Buy One Biotech Stock in April, It Better Be One of These 3 Names",
    "published": 1712857753,
    "posting_price": 48.6173655,
    "close_price": 47.32629776,
    "percent_change": -2.65556911
  },
  {
    "title": "ALX Oncology (ALXO) Posts Upbeat Results From Lymphoma Study",
    "published": 1712842200,
    "posting_price": 48.6173655,
    "close_price": 47.32629776,
    "percent_change": -2.65556911
  },
  {
    "title": "Building a Better Future: Bristol Myers Squibb 2023 ESG Report",
    "published": 1712841000,
    "posting_price": 48.6173655,
    "close_price": 47.32629776,
    "percent_change": -2.65556911
  },
  {
    "title": "A Closer Look At Bristol-Myers Squibb Company's (NYSE:BMY) Impressive ROE",
    "published": 1712833227,
    "posting_price": 48.6173655,
    "close_price": 47.32629776,
    "percent_change": -2.65556911
  },
  {
    "title": "May 31st Options Now Available For Bristol Myers Squibb (BMY)",
    "published": 1712828580,
    "posting_price": 48.6173655,
    "close_price": 47.32629776,
    "percent_change": -2.65556911
  },
  {
    "title": "The $5 BILLION Reason Alpine Immune Sciences (ALPN) Stock Is Up 30% Today",
    "published": 1712825520,
    "posting_price": 48.6173655,
    "close_price": 47.32629776,
    "percent_change": -2.65556911
  },
  {
    "title": "This Is What Whales Are Betting On Bristol-Myers Squibb",
    "published": 1712807400,
    "posting_price": 48.6173655,
    "close_price": 47.32629776,
    "percent_change": -2.65556911
  },
  {
    "title": "Biotech Stock Roundup: MRNA Up on Vaccine Data, BMY's Updates & More News",
    "published": 1712769540,
    "posting_price": 49.1761876,
    "close_price": 48.45357513,
    "percent_change": -1.46943573
  },
  {
    "title": "The Pharmaceutical Industry Finds Itself At A Historical Crossroads",
    "published": 1712767671,
    "posting_price": 49.1761876,
    "close_price": 48.45357513,
    "percent_change": -1.46943573
  },
  {
    "title": "2 High-Yield Dividend Stocks Billionaires Are Buying Hand Over Fist",
    "published": 1712743440,
    "posting_price": 49.1761876,
    "close_price": 48.45357513,
    "percent_change": -1.46943573
  },
  {
    "title": "Hold Rating on Bristol-Myers Squibb Amid Promising Yet Incomplete KarXT Schizophrenia Trial Data",
    "published": 1712711940,
    "posting_price": 49.1761876,
    "close_price": 48.45357513,
    "percent_change": -1.46943573
  },
  {
    "title": "Bristol Myers Squibb (BMY) Surpasses Market Returns: Some Facts Worth Knowing",
    "published": 1712699419,
    "posting_price": 49.26290174,
    "close_price": 49.71573639,
    "percent_change": 0.91922042
  },
  {
    "title": "Bristol Myers (BMY) Reports Positive Colorectal Cancer Study Data",
    "published": 1712683620,
    "posting_price": 49.26290174,
    "close_price": 49.71573639,
    "percent_change": 0.91922042
  },
  {
    "title": "Bristol Myers: cancer treatment results",
    "published": 1712656359,
    "posting_price": 49.26290174,
    "close_price": 49.71573639,
    "percent_change": 0.91922042
  },
  {
    "title": "3 Dividend Growth Stocks With Yields Above 3% That You Can Buy and Hold for the Next Decade",
    "published": 1712650860,
    "posting_price": 49.26290174,
    "close_price": 49.71573639,
    "percent_change": 0.91922042
  },
  {
    "title": "Upcoming Catalysts Position Perrigo For Sustained Long-Term Dividend Growth",
    "published": 1712641773,
    "posting_price": 49.26290174,
    "close_price": 49.71573639,
    "percent_change": 0.91922042
  },
  {
    "title": "Bristol-Myers Squibb snaps a six day losing spell",
    "published": 1712632980,
    "posting_price": 49.26290174,
    "close_price": 49.71573639,
    "percent_change": 0.91922042
  },
  {
    "title": "Bristol Myers Squibb's Acquired Adagrasib Combo Therapy May Benefit Colorectal Cancer Patients With Certain Mutation",
    "published": 1712606451,
    "posting_price": 49.40742081,
    "close_price": 49.23399353,
    "percent_change": -0.35101464
  },
  {
    "title": "Bristol Myers (BMY) Gets FDA Nod for Label Expansion of Abecma",
    "published": 1712597220,
    "posting_price": 49.40742081,
    "close_price": 49.23399353,
    "percent_change": -0.35101464
  },
  {
    "title": "KRAZATI (adagrasib) in Combination with Cetuximab Demonstrates Clinically Meaningful Activity as a Targeted Treatment Option for Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC)",
    "published": 1712590200,
    "posting_price": 49.40742081,
    "close_price": 49.23399353,
    "percent_change": -0.35101464
  },
  {
    "title": "IN BRIEF: Bristol-Myers unveils positive data on cancer drug adagrasib",
    "published": 1712588220,
    "posting_price": 49.40742081,
    "close_price": 49.23399353,
    "percent_change": -0.35101464
  },
  {
    "title": "FDA Expands J&J's (JNJ) Carvykti Label in Multiple Myeloma",
    "published": 1712583600,
    "posting_price": 49.40742081,
    "close_price": 49.23399353,
    "percent_change": -0.35101464
  },
  {
    "title": "Bristol Myers releases encouraging data for Krazati in colorectal cancer",
    "published": 1712574300,
    "posting_price": 49.40742081,
    "close_price": 49.23399353,
    "percent_change": -0.35101464
  },
  {
    "title": "Bristol Myers Squibb Releases 2023 ESG Report Demonstrating Progress and Setting New Long-Term Goals",
    "published": 1712574000,
    "posting_price": 49.40742081,
    "close_price": 49.23399353,
    "percent_change": -0.35101464
  },
  {
    "title": "Bristol Myers reports positive Phase 3 data for schizophrenia drug",
    "published": 1712572920,
    "posting_price": 49.40742081,
    "close_price": 49.23399353,
    "percent_change": -0.35101464
  },
  {
    "title": "Bristol Myers: Krazati plus cetuximab showed ORR of 34%, PFS of 6.9 months",
    "published": 1712572440,
    "posting_price": 49.40742081,
    "close_price": 49.23399353,
    "percent_change": -0.35101464
  },
  {
    "title": "Bristol Myers' $14B Bet On Schizophrenia - Drug Cuts Symptoms Without Common Side Effect Of Weight Gain Associated With Other Antipsychotics",
    "published": 1712568780,
    "posting_price": 49.40742081,
    "close_price": 49.23399353,
    "percent_change": -0.35101464
  },
  {
    "title": "U.S. FDA Approves Bristol Myers Squibb and 2seventy bio's Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma after Two Prior Lines of Therapy",
    "published": 1712561309,
    "posting_price": 49.40742081,
    "close_price": 49.23399353,
    "percent_change": -0.35101464
  },
  {
    "title": "Bristol Myers: new data on schizophrenia",
    "published": 1712551965,
    "posting_price": 49.40742081,
    "close_price": 49.23399353,
    "percent_change": -0.35101464
  },
  {
    "title": "Bristol-Myers Squibb\u2019s Hold Rating: Balancing KarXT\u2019s Efficacy and Safety with Financial Uncertainties",
    "published": 1712551680,
    "posting_price": 49.40742081,
    "close_price": 49.23399353,
    "percent_change": -0.35101464
  },
  {
    "title": "DGI For The DIY: 2023 Dividend Portfolio Review",
    "published": 1712546542,
    "posting_price": 49.40742081,
    "close_price": 49.23399353,
    "percent_change": -0.35101464
  },
  {
    "title": "Bristol-Myers Squibb treatment improves schizophrenia symptoms in test",
    "published": 1712546340,
    "posting_price": 49.40742081,
    "close_price": 49.23399353,
    "percent_change": -0.35101464
  },
  {
    "title": "Morgan Stanley sees Fed rate cut fueling biotech stocks",
    "published": 1712493540
  },
  {
    "title": "Morgan Stanley sees Fed rate cut fueling biotech stock performance",
    "published": 1712493180
  },
  {
    "title": "Possible Bearish Signals With Bristol-Myers Squibb Insiders Disposing Stock",
    "published": 1712487669
  },
  {
    "title": "Phathom Pharma, Rhythm, Vaxcyte most likely takeover targets in pharma - analyst",
    "published": 1712473500
  },
  {
    "title": "Week In Review: ProfoundBio, A Seattle-Suzhou ADC Biotech, Acquired By Genmab For $1.8 Billion",
    "published": 1712471400
  },
  {
    "title": "Bristol Myers presents new data from Phase 3 EMERGENT program evaluating KarXT",
    "published": 1712468640
  },
  {
    "title": "Bristol Myers presents new interim long-term efficacy data from EMERGENT-4 trial",
    "published": 1712468100
  },
  {
    "title": "Bristol Myers Squibb Presents New Pooled Interim Long-Term Safety and Metabolic Outcomes Data from the EMERGENT Program Evaluating KarXT in Schizophrenia at the 2024 Annual Congress of the Schizophrenia International Research Society",
    "published": 1712423700
  },
  {
    "title": "Bristol Myers' schizophrenia drug reduces symptoms without weight gain in late-stage studies",
    "published": 1712423700
  },
  {
    "title": "Bristol Myers Squibb Presents New Interim Long-Term Efficacy Data from the EMERGENT-4 Trial Evaluating KarXT in Schizophrenia at the 2024 Annual Congress of the Schizophrenia International Research Society",
    "published": 1712423700
  },
  {
    "title": "5 Relatively Secure And Cheap Dividend Stocks To Invest In - April 2024",
    "published": 1712395800
  },
  {
    "title": "Johnson & Johnson wins FDA nod for Carvykti label expansion",
    "published": 1712389260
  },
  {
    "title": "Bristol Myers highlights safety of KarXT schizophrenia therapy",
    "published": 1712370240
  },
  {
    "title": "The 3 Most Undervalued Biotech Stocks to Buy in April 2024",
    "published": 1712339647,
    "posting_price": 49.32070714,
    "close_price": 49.445961,
    "percent_change": 0.25395796
  },
  {
    "title": "IN BRIEF: Bristol-Myers secures US FDA approval for Abecma",
    "published": 1712323800,
    "posting_price": 49.32070714,
    "close_price": 49.445961,
    "percent_change": 0.25395796
  },
  {
    "title": "UPDATE 2-US FDA allows expanded use of Bristol Myers' cell therapy for blood cancer",
    "published": 1712323301,
    "posting_price": 49.32070714,
    "close_price": 49.445961,
    "percent_change": 0.25395796
  },
  {
    "title": "U.S. FDA Approves Bristol Myers Squibb and 2seventy bio\u2019s Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy",
    "published": 1712322300,
    "posting_price": 49.32070714,
    "close_price": 49.445961,
    "percent_change": 0.25395796
  },
  {
    "title": "FDA Approves Bristol-Myers/2seventy Bio's Abecma For Earlier Use In Pretreated Blood Cancer Patients With Updated Boxed Warning On Secondary Cancer",
    "published": 1712321040,
    "posting_price": 49.32070714,
    "close_price": 49.445961,
    "percent_change": 0.25395796
  },
  {
    "title": "Bristol Myers CAR-T therapy approved by FDA for earlier myeloma use",
    "published": 1712316300,
    "posting_price": 49.32070714,
    "close_price": 49.445961,
    "percent_change": 0.25395796
  },
  {
    "title": "Bristol Myers: FDA approves Abecma in multiple myeloma",
    "published": 1712309515,
    "posting_price": 49.32070714,
    "close_price": 49.445961,
    "percent_change": 0.25395796
  },
  {
    "title": "US FDA allows expanded use of Bristol Myers' cell therapy for blood cancer",
    "published": 1712308901,
    "posting_price": 49.32070714,
    "close_price": 49.445961,
    "percent_change": 0.25395796
  },
  {
    "title": "Biggest stock mover today: GCTS, TSVT, GRIN, ANGO, ATUS, and more",
    "published": 1712308620,
    "posting_price": 49.32070714,
    "close_price": 49.445961,
    "percent_change": 0.25395796
  },
  {
    "title": "U.S. FDA allows expanded use of Bristol Myers' cell therapy",
    "published": 1712308144,
    "posting_price": 49.32070714,
    "close_price": 49.445961,
    "percent_change": 0.25395796
  },
  {
    "title": "Bristol Myers, 2seventy bio receive FDA approval for Abecma to treat multiple myeloma",
    "published": 1712306280,
    "posting_price": 49.32070714,
    "close_price": 49.445961,
    "percent_change": 0.25395796
  },
  {
    "title": "Bristol Myers, 2seventy Bio's Abecma approved by U.S. FDA",
    "published": 1712304540,
    "posting_price": 49.32070714,
    "close_price": 49.445961,
    "percent_change": 0.25395796
  },
  {
    "title": "Bristol Myers Squibb Co. stock underperforms Friday when compared to competitors",
    "published": 1712288700,
    "posting_price": 49.32070714,
    "close_price": 49.445961,
    "percent_change": 0.25395796
  },
  {
    "title": "Biotech Stock Roundup: IRON, VERV Down on Study Updates, BMYs Drug News & More",
    "published": 1712251260,
    "posting_price": 50.04332279,
    "close_price": 49.52304459,
    "percent_change": -1.03965558
  },
  {
    "title": "Investors Heavily Search Bristol Myers Squibb Company (BMY): Here is What You Need to Know",
    "published": 1712235614,
    "posting_price": 50.04332279,
    "close_price": 49.52304459,
    "percent_change": -1.03965558
  },
  {
    "title": "Merck puts KRAS cancer drug competitor to the test",
    "published": 1712230680,
    "posting_price": 50.04332279,
    "close_price": 49.52304459,
    "percent_change": -1.03965558
  },
  {
    "title": "Top buy-rated stocks and sell-rated stocks within Health Care - Citi",
    "published": 1712225880,
    "posting_price": 50.04332279,
    "close_price": 49.52304459,
    "percent_change": -1.03965558
  },
  {
    "title": "May 24th Options Now Available For Bristol Myers Squibb (BMY)",
    "published": 1712223360,
    "posting_price": 50.04332279,
    "close_price": 49.52304459,
    "percent_change": -1.03965558
  },
  {
    "title": "Big Pharma Stocks Need a Rethink. Investors Keep Making the Same Mistake.",
    "published": 1712206800,
    "posting_price": 50.04332279,
    "close_price": 49.52304459,
    "percent_change": -1.03965558
  },
  {
    "title": "Bristol Myers (BMY) Wins EC Nod for Reblozyl Label Expansion",
    "published": 1712150040,
    "posting_price": 50.23933864,
    "close_price": 49.69646835,
    "percent_change": -1.08056815
  },
  {
    "title": "Bristol Myers wins label expansion for anemia therapy in EU",
    "published": 1712146200,
    "posting_price": 50.23933864,
    "close_price": 49.69646835,
    "percent_change": -1.08056815
  },
  {
    "title": "Bristol-Myers Squibb (NYSE:BMY) investors are sitting on a loss of 20% if they invested a year ago",
    "published": 1712145637,
    "posting_price": 50.23933864,
    "close_price": 49.69646835,
    "percent_change": -1.08056815
  },
  {
    "title": "Bristol-Myers Squibb Co's Dividend Analysis",
    "published": 1712142155,
    "posting_price": 50.23933864,
    "close_price": 49.69646835,
    "percent_change": -1.08056815
  },
  {
    "title": "Bristol Myers: European Commission expands approval of Reblozyl",
    "published": 1712120220,
    "posting_price": 50.23933864,
    "close_price": 49.69646835,
    "percent_change": -1.08056815
  },
  {
    "title": "Bristol Myers: EU approval extended for Reblozyl",
    "published": 1712119372,
    "posting_price": 50.23933864,
    "close_price": 49.69646835,
    "percent_change": -1.08056815
  },
  {
    "title": "Wells Fargo Sticks to Its Hold Rating for Bristol-Myers Squibb (BMY)",
    "published": 1712117820,
    "posting_price": 50.23933864,
    "close_price": 49.69646835,
    "percent_change": -1.08056815
  },
  {
    "title": "Standard BioTools announces multi-year agreement with Bristol Myers",
    "published": 1712113380,
    "posting_price": 50.23933864,
    "close_price": 49.69646835,
    "percent_change": -1.08056815
  },
  {
    "title": "European Commission Expands Approval of Bristol Myers Squibb\u2019s Reblozyl\u00ae (luspatercept) to Include First-Line Treatment of Transfusion-Dependent Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (LR-MDS)",
    "published": 1712102880,
    "posting_price": 50.23933864,
    "close_price": 49.69646835,
    "percent_change": -1.08056815
  },
  {
    "title": "Bristol Myers Squibb (BMY) Stock Moves -0.47%: What You Should Know",
    "published": 1712094619,
    "posting_price": 50.57267902,
    "close_price": 50.22981644,
    "percent_change": -0.67796009
  },
  {
    "title": "Bristol Myers Squibb Releases 2023 Environmental, Social and Governance Report Demonstrating Progress and Setting New Long-Term Goals",
    "published": 1712082600,
    "posting_price": 50.57267902,
    "close_price": 50.22981644,
    "percent_change": -0.67796009
  },
  {
    "title": "Merger Mania: 3 Potential Takeover Targets to Watch for Lucrative Buyouts",
    "published": 1712056740,
    "posting_price": 50.57267902,
    "close_price": 50.22981644,
    "percent_change": -0.67796009
  },
  {
    "title": "Zai Lab Partner Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI Meets Primary Endpoint",
    "published": 1712049693,
    "posting_price": 50.57267902,
    "close_price": 50.22981644,
    "percent_change": -0.67796009
  },
  {
    "title": "Ex-Dividend Reminder: Bristol Myers Squibb, Preferred Bank and Kite Realty Group Trust",
    "published": 1712049420,
    "posting_price": 50.57267902,
    "close_price": 50.22981644,
    "percent_change": -0.67796009
  },
  {
    "title": "Bristol-Myers Squibb Is A Speculative Buy On Price Action (Technical Analysis)",
    "published": 1712005080,
    "posting_price": 51.59175242,
    "close_price": 50.4679184,
    "percent_change": -2.17832108
  },
  {
    "title": "The Bargain Hunter\u2019s Dream: 3 Underpriced Stocks Poised for Massive Gains",
    "published": 1711995376,
    "posting_price": 51.59175242,
    "close_price": 50.4679184,
    "percent_change": -2.17832108
  },
  {
    "title": "Bristol Myers' (BMY) Zeposia Fails Crohn's Disease Study",
    "published": 1711989960,
    "posting_price": 51.59175242,
    "close_price": 50.4679184,
    "percent_change": -2.17832108
  },
  {
    "title": "Zai Lab reports Krazati lung cancer study meets primary endpoint",
    "published": 1711965600,
    "posting_price": 51.59175242,
    "close_price": 50.4679184,
    "percent_change": -2.17832108
  },
  {
    "title": "One Good, One Bad News For Bristol Myers Squibb's Marketed Drugs: Details",
    "published": 1711961400,
    "posting_price": 51.59175242,
    "close_price": 50.4679184,
    "percent_change": -2.17832108
  },
  {
    "title": "Zai Lab Partner Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRASG12C-Mutated Locally Advanced or Metastatic...",
    "published": 1711956600,
    "posting_price": 51.59175242,
    "close_price": 50.4679184,
    "percent_change": -2.17832108
  },
  {
    "title": "Zai Lab, Bristol Myers: Krazati confirmatory trial meets PFS primary endpoints",
    "published": 1711953600,
    "posting_price": 51.59175242,
    "close_price": 50.4679184,
    "percent_change": -2.17832108
  },
  {
    "title": "Cytokinetics, Incorporated: Buyout Speculation Persists",
    "published": 1711951699,
    "posting_price": 51.59175242,
    "close_price": 50.4679184,
    "percent_change": -2.17832108
  },
  {
    "title": "Bristol Myers Squibb Expands Health Equity Grant Initiatives to Improve Health Outcomes",
    "published": 1711945988,
    "posting_price": 51.59175242,
    "close_price": 50.4679184,
    "percent_change": -2.17832108
  },
  {
    "title": "10 Dividend Growth Stocks: March 2024",
    "published": 1711943087,
    "posting_price": 51.59175242,
    "close_price": 50.4679184,
    "percent_change": -2.17832108
  }
]